Skip to main content
Top
Published in: Clinical and Experimental Medicine 2/2016

01-05-2016 | Review Article

The synovio-entheseal complex in enthesoarthritis

Authors: Angelo De Cata, Michele Inglese, Rosa Rubino, Francesca Molinaro, Gianluigi Mazzoccoli

Published in: Clinical and Experimental Medicine | Issue 2/2016

Login to get access

Abstract

The group of diseases classified as seronegative spondyloarthritis or enthesoarthritis is characterized by typical osteoarticular and extra-articular manifestations. Diverse patterns of disease can affect different members of the same family and may show different features in the same patient, with clinical overlaps thwarting the differential diagnosis. An anatomo-pathological hallmark in enthesoarthritis is the inflammatory process in the synovio-entheseal sites. The inflammatory microenvironment of synovio-entheseal complex, named enthesitis, is characterized, after an initial inflammatory/erosive phase, by a subsequent phase of neobone apposition, which seems to progress independently from the previous erosive phase, suggesting that the physiopathogenetic mechanisms that underlay the two phases are driven by different pivots. The structural damage is characterized by excessive neobone formation, with the syndesmophyte as a typical lesion. The process underlying their formation is not fully understood, although there are many useful information to clarify the physiopathogenetic puzzle. The primum movens of the enthesitic process is the micro-trauma to which entheses are subject, especially in the lower limbs, for biomechanical reasons. The inflammatory process is facilitated by the sequential structure of the organ enthesis, constitutionally devoid of sub-enthesitic cortical bone and closely related to the underlying trabecular bone and the medullary vascular system. The reparative attempt from the vascular system, thanks to the activating action of certain loco-regional cytokines, such as TNF α, conditions the possible deposit in the enthesis of molecules derived from other organic sites and able, especially in HLA-B27+ subjects, to activate and self-renew an immune-mediated inflammatory process following the initial mechanical process.
Literature
1.
go back to reference Benjamin M, McGonagle D. The anatomical basis for disease localisation in seronegative spondyloarthropathy at entheses and related sites. J Anat. 2011;199:503–26.CrossRef Benjamin M, McGonagle D. The anatomical basis for disease localisation in seronegative spondyloarthropathy at entheses and related sites. J Anat. 2011;199:503–26.CrossRef
2.
go back to reference Benjamin M. The enthesis organ concept and its relevance to the spondyloarthropathies. In: Lopez-Larrea C, Diaz-Pena R, editors. Molecular mechanisms of spondyloarthropathies, vol. 4. New York: Landes Bioscience and Springer Sciences Business Media; 2009. p. 57–70.CrossRef Benjamin M. The enthesis organ concept and its relevance to the spondyloarthropathies. In: Lopez-Larrea C, Diaz-Pena R, editors. Molecular mechanisms of spondyloarthropathies, vol. 4. New York: Landes Bioscience and Springer Sciences Business Media; 2009. p. 57–70.CrossRef
3.
go back to reference Benjamin M, Toumi H, Suzuki D, Redman S, Emery P, McGonagle D. Microdamage and altered vascularity at the enthesis-bone interface provides an anatomic explanation for Bone involvement in the HLA-B-27-associated spondyloarthritides and allied conditions. Arth Rheum. 2007;56(1):224–33.CrossRef Benjamin M, Toumi H, Suzuki D, Redman S, Emery P, McGonagle D. Microdamage and altered vascularity at the enthesis-bone interface provides an anatomic explanation for Bone involvement in the HLA-B-27-associated spondyloarthritides and allied conditions. Arth Rheum. 2007;56(1):224–33.CrossRef
4.
go back to reference McGonagle D, Lories RJ, Tan AL, Benjamin M. The concept of a “synovio-entheseal complex” and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arth Rheum. 2007;56:2482–91.CrossRef McGonagle D, Lories RJ, Tan AL, Benjamin M. The concept of a “synovio-entheseal complex” and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arth Rheum. 2007;56:2482–91.CrossRef
5.
go back to reference Kahn MF, Chamot AM. SAPHO syndrome. Rheum Dis Clin North Am. 1992;18:225–46.PubMed Kahn MF, Chamot AM. SAPHO syndrome. Rheum Dis Clin North Am. 1992;18:225–46.PubMed
6.
go back to reference Chamot AM, Benhamou CL, Kahn MF, Beraneck L, Kaplan G, Prost A. Acne-pustolosis-hyperostosis-osteitis syndrome: results of a National survey, 85 cases (review). Rev Rhum Mal Osteoartic. 1987;54:187–96.PubMed Chamot AM, Benhamou CL, Kahn MF, Beraneck L, Kaplan G, Prost A. Acne-pustolosis-hyperostosis-osteitis syndrome: results of a National survey, 85 cases (review). Rev Rhum Mal Osteoartic. 1987;54:187–96.PubMed
7.
go back to reference McGonagle D, Stockwin L, Isaacs J, Emery P. An enthesitis based model for the pathogenesis of spondyloathropathy: additive effects of microbial adjuvant and biomechanical factors at disease sites. J Rheumatol. 2001;28:2155–9.PubMed McGonagle D, Stockwin L, Isaacs J, Emery P. An enthesitis based model for the pathogenesis of spondyloathropathy: additive effects of microbial adjuvant and biomechanical factors at disease sites. J Rheumatol. 2001;28:2155–9.PubMed
8.
go back to reference Maksymowych WP. Ankylosing spondylitis: at the interface of bone and cartilage. J Rheumatol. 2000;27:2295–301.PubMed Maksymowych WP. Ankylosing spondylitis: at the interface of bone and cartilage. J Rheumatol. 2000;27:2295–301.PubMed
10.
go back to reference Lories RJ, Derese I, Luyten FP. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest. 2005;115:1571–9.PubMedPubMedCentralCrossRef Lories RJ, Derese I, Luyten FP. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest. 2005;115:1571–9.PubMedPubMedCentralCrossRef
11.
go back to reference Lories RJ, Daans M, Derese I, et al. Nogging haploinsufficiency differentially affects tissue responses in destructive and remodeling arthritis. Arth Rheum. 2006;54:1736–46.CrossRef Lories RJ, Daans M, Derese I, et al. Nogging haploinsufficiency differentially affects tissue responses in destructive and remodeling arthritis. Arth Rheum. 2006;54:1736–46.CrossRef
12.
go back to reference Lories RJ, Derese I, de Bari C, Luyten FP. Evidence for uncoupling of inflammation and joint remodelling in a mouse model of spondylarthritis. Arth Rheum. 2007;56:489–97.CrossRef Lories RJ, Derese I, de Bari C, Luyten FP. Evidence for uncoupling of inflammation and joint remodelling in a mouse model of spondylarthritis. Arth Rheum. 2007;56:489–97.CrossRef
13.
go back to reference Lories RJ, Derese I, Luyten FP. Inhibition of osteoclast does not prevent joint ankylosis in a mouse model of spondyloartrhritis. Rheumatology. 2008;47:605–8.PubMedCrossRef Lories RJ, Derese I, Luyten FP. Inhibition of osteoclast does not prevent joint ankylosis in a mouse model of spondyloartrhritis. Rheumatology. 2008;47:605–8.PubMedCrossRef
14.
go back to reference Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodelling. Nat Med. 2007;13:156–63.PubMedCrossRef Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodelling. Nat Med. 2007;13:156–63.PubMedCrossRef
16.
go back to reference Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human tumor necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991;10:4025–31.PubMedPubMedCentral Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human tumor necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991;10:4025–31.PubMedPubMedCentral
17.
go back to reference Shealy DJ, Wooley PH, Emmell E, et al. Anti-TNF alpha antibody allows healing of joint damage in polyarthritic transgenic mice. Arthritis Res. 2002;4:R7.PubMedPubMedCentralCrossRef Shealy DJ, Wooley PH, Emmell E, et al. Anti-TNF alpha antibody allows healing of joint damage in polyarthritic transgenic mice. Arthritis Res. 2002;4:R7.PubMedPubMedCentralCrossRef
18.
go back to reference Pettit AR, Ji H, von Stechow D, et al. TRANCE/RANKL knockout mice are protected from bone erosionin a serum transfer model of arthritis. Am J Pathol. 2001;159:1689–99.PubMedPubMedCentralCrossRef Pettit AR, Ji H, von Stechow D, et al. TRANCE/RANKL knockout mice are protected from bone erosionin a serum transfer model of arthritis. Am J Pathol. 2001;159:1689–99.PubMedPubMedCentralCrossRef
19.
go back to reference Haynes DR, Barg E, Crotti TN, et al. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. Rheumatology. 2003;42:123–34.PubMedCrossRef Haynes DR, Barg E, Crotti TN, et al. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. Rheumatology. 2003;42:123–34.PubMedCrossRef
20.
go back to reference Vandooren B, Cantaert T, Noordenbos T, Tak PP, Baeten D. The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation. Arthritis Rheum. 2008;58:718–29.PubMedCrossRef Vandooren B, Cantaert T, Noordenbos T, Tak PP, Baeten D. The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation. Arthritis Rheum. 2008;58:718–29.PubMedCrossRef
21.
go back to reference Kotake S, Udagawa N, Hakoda M, et al. Activated human T cells directly induce osteoclastogenesis from human monocytis: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum. 2001;44:1003–12.PubMedCrossRef Kotake S, Udagawa N, Hakoda M, et al. Activated human T cells directly induce osteoclastogenesis from human monocytis: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum. 2001;44:1003–12.PubMedCrossRef
22.
go back to reference Crotti TN, Flannery M, Walsh NC, Fleming JD, Goldring SR, McHugh KP. NFATc1 directly induces the human beta3 integrin gene in osteoclast differentiation. J Muscoloskeletal Neuronal Interact. 2005;5:335–7. Crotti TN, Flannery M, Walsh NC, Fleming JD, Goldring SR, McHugh KP. NFATc1 directly induces the human beta3 integrin gene in osteoclast differentiation. J Muscoloskeletal Neuronal Interact. 2005;5:335–7.
24.
go back to reference Crotti TN, Sharma SM, Fleming JD, et al. PU.1 and NFATc1 mediate osteoclastic induction of the mouse beta3 integrin promoter. J Cell Physiol. 2008;215:636–44.PubMedCrossRef Crotti TN, Sharma SM, Fleming JD, et al. PU.1 and NFATc1 mediate osteoclastic induction of the mouse beta3 integrin promoter. J Cell Physiol. 2008;215:636–44.PubMedCrossRef
25.
go back to reference Shen Z, Crotti TN, Flannery MR, Matsuzaki K, Goldring SR, McHugh KP. A novel promoter regulates calcitonin receptor gene expression in human osteoclasts. Biochim Biophys Acta. 2007;1769:659–67.PubMedCrossRef Shen Z, Crotti TN, Flannery MR, Matsuzaki K, Goldring SR, McHugh KP. A novel promoter regulates calcitonin receptor gene expression in human osteoclasts. Biochim Biophys Acta. 2007;1769:659–67.PubMedCrossRef
26.
go back to reference van der Heijde D, Landewé R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 2008;58:1324–31.PubMedCrossRef van der Heijde D, Landewé R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 2008;58:1324–31.PubMedCrossRef
27.
go back to reference van der Heijde D, Landewé R, Baraliakos X, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum. 2008;58:3063–70.PubMedCrossRef van der Heijde D, Landewé R, Baraliakos X, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum. 2008;58:3063–70.PubMedCrossRef
28.
go back to reference Van der Heijde D. Adalimumab therapy for ankylosing spondylitis over two years does not demonstrate inhibition of radiographic progression compared with a historical control group. Arthr Rheum 2008;58(Suppl):5413; abstract 670. Van der Heijde D. Adalimumab therapy for ankylosing spondylitis over two years does not demonstrate inhibition of radiographic progression compared with a historical control group. Arthr Rheum 2008;58(Suppl):5413; abstract 670.
29.
go back to reference Baraliakos X, Listing J, Brandt J, et al. Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology (Oxford). 2007;46:1450–3.CrossRef Baraliakos X, Listing J, Brandt J, et al. Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology (Oxford). 2007;46:1450–3.CrossRef
30.
go back to reference Braun J, Baraliakos X, Listing J, et al. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis. 2008;67(3):340–5.PubMedCrossRef Braun J, Baraliakos X, Listing J, et al. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis. 2008;67(3):340–5.PubMedCrossRef
31.
go back to reference Wanders A, Dv Heijde, Landewé R, et al. Non steroidal anti-inflammatory drugs induce radiographic progression in patients with ankylosing spondylitis: a randomized clinic trial. Arthritis Rheum. 2005;52:1756–65.PubMedCrossRef Wanders A, Dv Heijde, Landewé R, et al. Non steroidal anti-inflammatory drugs induce radiographic progression in patients with ankylosing spondylitis: a randomized clinic trial. Arthritis Rheum. 2005;52:1756–65.PubMedCrossRef
32.
go back to reference Boersma JW. Retardation of ossification on the lumbar vertebral column in ankylosing spondylitis by means of phenylbutazone. Scan J Rheum. 1976;5:60–4. Boersma JW. Retardation of ossification on the lumbar vertebral column in ankylosing spondylitis by means of phenylbutazone. Scan J Rheum. 1976;5:60–4.
33.
go back to reference Krischak GD, Augat P, Blakytny R, Claes L, Kinzl L, Beck A. The non steroidal anti inflammatory drug diclofenac reduces appearance of osteoblasts in bone defect healing in rats. Arch Orthop Trauma Surg. 2007;127:453–8.PubMedCrossRef Krischak GD, Augat P, Blakytny R, Claes L, Kinzl L, Beck A. The non steroidal anti inflammatory drug diclofenac reduces appearance of osteoblasts in bone defect healing in rats. Arch Orthop Trauma Surg. 2007;127:453–8.PubMedCrossRef
34.
go back to reference Qian J, Xie J, Hong S, et al. Dickkopf-1 (DKK1) is a widely expressed and potent tumor associated antigen in multiple myeloma. Blood 2007;110:1587–1594.PubMedPubMedCentralCrossRef Qian J, Xie J, Hong S, et al. Dickkopf-1 (DKK1) is a widely expressed and potent tumor associated antigen in multiple myeloma. Blood 2007;110:1587–1594.PubMedPubMedCentralCrossRef
35.
go back to reference Claudepierre P, Wendling D. Are inflammation and ossification on separate tracks in ankylosing spondylitis? Joint Bone Spine. 2008;75:520–2.PubMedCrossRef Claudepierre P, Wendling D. Are inflammation and ossification on separate tracks in ankylosing spondylitis? Joint Bone Spine. 2008;75:520–2.PubMedCrossRef
36.
go back to reference François RJ, Neure L, Sieper J, Braun J. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumor necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann Rheum Dis. 2006;65:713–20.PubMedPubMedCentralCrossRef François RJ, Neure L, Sieper J, Braun J. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumor necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann Rheum Dis. 2006;65:713–20.PubMedPubMedCentralCrossRef
37.
go back to reference Braun J, Bollow M, Neure L, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arth Rheum. 1995;38:499–505.CrossRef Braun J, Bollow M, Neure L, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arth Rheum. 1995;38:499–505.CrossRef
39.
go back to reference Claudepierre P, Rymer JC, Authier FJ, et al. A relationship between TGF-beta 1 or IL-6 plasma levels and clinical features of spondyloarthropathies. Br J Rheumatol. 1997;36:400–1.PubMedCrossRef Claudepierre P, Rymer JC, Authier FJ, et al. A relationship between TGF-beta 1 or IL-6 plasma levels and clinical features of spondyloarthropathies. Br J Rheumatol. 1997;36:400–1.PubMedCrossRef
40.
go back to reference Wendling D, Cedoz JP, Racadot E, Dumoulin G. Serum IL17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine. 2007;74:304–5.PubMedCrossRef Wendling D, Cedoz JP, Racadot E, Dumoulin G. Serum IL17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine. 2007;74:304–5.PubMedCrossRef
42.
go back to reference Li P, Schwarz EM, O’Keefe RJ, et al. Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11b high osteoclast precursor in tumor necrosis factor alpha-transgenic mice. Arthritis Rheum. 2004;50:265–76.PubMedCrossRef Li P, Schwarz EM, O’Keefe RJ, et al. Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11b high osteoclast precursor in tumor necrosis factor alpha-transgenic mice. Arthritis Rheum. 2004;50:265–76.PubMedCrossRef
43.
go back to reference Kaneki H, Guo R, Chen D, et al. Tumor necrosis factor promotes Runx2 degradation through up-regulation of Smurf1 and Smurf2 in osteoblasts. J Biol Chem. 2006;281:4326–33.PubMedPubMedCentralCrossRef Kaneki H, Guo R, Chen D, et al. Tumor necrosis factor promotes Runx2 degradation through up-regulation of Smurf1 and Smurf2 in osteoblasts. J Biol Chem. 2006;281:4326–33.PubMedPubMedCentralCrossRef
44.
go back to reference Ji H, Pettit A, Ohmura K, et al. Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induces arthritis. J Exp Med. 2002;196:77–85.PubMedPubMedCentralCrossRef Ji H, Pettit A, Ohmura K, et al. Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induces arthritis. J Exp Med. 2002;196:77–85.PubMedPubMedCentralCrossRef
46.
47.
go back to reference Fonseca JE, Santos MJ, Canhão H, Choy E. IL6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev. 2009;8:538–42.PubMedCrossRef Fonseca JE, Santos MJ, Canhão H, Choy E. IL6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev. 2009;8:538–42.PubMedCrossRef
48.
go back to reference Kato A, Matsuo S, Takai H, Uchiyama Y, Mihara M, Suzuki M. Early effects of tocilizumab on bone and bone marrow lesions in a collagen-induced arthritis monkey model. Exp Mol Pathol. 2008;84:262–70.PubMedCrossRef Kato A, Matsuo S, Takai H, Uchiyama Y, Mihara M, Suzuki M. Early effects of tocilizumab on bone and bone marrow lesions in a collagen-induced arthritis monkey model. Exp Mol Pathol. 2008;84:262–70.PubMedCrossRef
49.
go back to reference Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(1):88–96.PubMedPubMedCentralCrossRef Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(1):88–96.PubMedPubMedCentralCrossRef
50.
go back to reference Ogura H, Murakami M, Okuyama Y, et al. IL17 promotes autoimmunity by triggering a positive feed-back loop via IL6 induction. Immunity. 2008;29:628–36.PubMedCrossRef Ogura H, Murakami M, Okuyama Y, et al. IL17 promotes autoimmunity by triggering a positive feed-back loop via IL6 induction. Immunity. 2008;29:628–36.PubMedCrossRef
51.
go back to reference Poole KE, van Bezooijen RL, Loveridge N, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005;19:1842–4.PubMed Poole KE, van Bezooijen RL, Loveridge N, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005;19:1842–4.PubMed
53.
go back to reference Walsh NC, Reinwald S, Manning CA, et al. Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J Bone Miner Res. 2009;24:1572–85.PubMedCrossRef Walsh NC, Reinwald S, Manning CA, et al. Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J Bone Miner Res. 2009;24:1572–85.PubMedCrossRef
54.
55.
go back to reference Moon RT, Kohn AD, De Ferrari GV, Kaykas A. Wnt and beta-catenin signaling: diseases and therapies. Nat Rev Genet. 2004;5:691–701.PubMedCrossRef Moon RT, Kohn AD, De Ferrari GV, Kaykas A. Wnt and beta-catenin signaling: diseases and therapies. Nat Rev Genet. 2004;5:691–701.PubMedCrossRef
56.
go back to reference Ijiri K, Nagayoshi R, Matsushita N, et al. Differential expression patterns of secreted frizzled related protein genes in synovial cells from patients with arthritis. J Rheumatol. 2002;29:2266–70.PubMed Ijiri K, Nagayoshi R, Matsushita N, et al. Differential expression patterns of secreted frizzled related protein genes in synovial cells from patients with arthritis. J Rheumatol. 2002;29:2266–70.PubMed
57.
go back to reference Arnett TR, Gibbons DC, Utting JC, et al. Hypoxia is a major regulator of osteoclast formation and bone resorption. J Cell Physiol. 2003;196:2–8.PubMedCrossRef Arnett TR, Gibbons DC, Utting JC, et al. Hypoxia is a major regulator of osteoclast formation and bone resorption. J Cell Physiol. 2003;196:2–8.PubMedCrossRef
58.
go back to reference Utting JC, Robins SP, Brandao-Burch A, Orriss IR, Behar J, Arnett TR. Hypoxia inhibits the growth, differentiation and bone forming capacity of rat osteoblasts. Exp Cell Res. 2006;312:1693–702.PubMedCrossRef Utting JC, Robins SP, Brandao-Burch A, Orriss IR, Behar J, Arnett TR. Hypoxia inhibits the growth, differentiation and bone forming capacity of rat osteoblasts. Exp Cell Res. 2006;312:1693–702.PubMedCrossRef
59.
go back to reference Brandao-Burch A, Utting JC, Orriss IR, Arnett TR. Acidosis inhibits bone formation by osteoblasts in vitro by preventing mineralization. Calcif Tissue Int. 2005;77:167–74.PubMedCrossRef Brandao-Burch A, Utting JC, Orriss IR, Arnett TR. Acidosis inhibits bone formation by osteoblasts in vitro by preventing mineralization. Calcif Tissue Int. 2005;77:167–74.PubMedCrossRef
60.
go back to reference Uderhardt S, Diarra D, Katzenbeisser J, et al. Blockade of Dickkopf 1 induces fusion of sacroiliac joints. Ann Rheum Dis. 2010;69(3):592–7.PubMedCrossRef Uderhardt S, Diarra D, Katzenbeisser J, et al. Blockade of Dickkopf 1 induces fusion of sacroiliac joints. Ann Rheum Dis. 2010;69(3):592–7.PubMedCrossRef
61.
go back to reference Li P, Schwarz EM, O’Keefe RJ, Ma L, Boyce BF, Xing L. RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclasts precursor but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis. J Bone Miner Res. 2004;19:207–13.PubMedCrossRef Li P, Schwarz EM, O’Keefe RJ, Ma L, Boyce BF, Xing L. RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclasts precursor but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis. J Bone Miner Res. 2004;19:207–13.PubMedCrossRef
62.
go back to reference Redlich K, Hayer S, Maier A, et al. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclast with osteoprotegerin. Arthritis Rheum. 2002;46:785–92.PubMedCrossRef Redlich K, Hayer S, Maier A, et al. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclast with osteoprotegerin. Arthritis Rheum. 2002;46:785–92.PubMedCrossRef
63.
go back to reference Cohen SB, Dore RK, Lane NE, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 2008;58:1299–309.PubMedCrossRef Cohen SB, Dore RK, Lane NE, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 2008;58:1299–309.PubMedCrossRef
64.
go back to reference Lencel P, Delplace S, Pilet P, et al. Cell-specific effects of TNF-alpha and IL-1 beta on alkaline phosphatase: implication for syndesmophyte formation and vascular calcification. Lab Invest. 2001;91:1434–42.CrossRef Lencel P, Delplace S, Pilet P, et al. Cell-specific effects of TNF-alpha and IL-1 beta on alkaline phosphatase: implication for syndesmophyte formation and vascular calcification. Lab Invest. 2001;91:1434–42.CrossRef
65.
go back to reference Pham T. Pathophysiology of ankylosing spondylitis: what’s new? Joint Bone Spine. 2008;75:656–60.PubMedCrossRef Pham T. Pathophysiology of ankylosing spondylitis: what’s new? Joint Bone Spine. 2008;75:656–60.PubMedCrossRef
66.
go back to reference Brown MA, Kennedy LG, MacGregor AJ, et al. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis Rheum. 1997;40:1823–8.PubMedCrossRef Brown MA, Kennedy LG, MacGregor AJ, et al. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis Rheum. 1997;40:1823–8.PubMedCrossRef
67.
go back to reference D’Amato M, Fiorillo MT, Carcassi C, et al. Relevance of residue 116 of HLA-B27 in determining susceptibility to ankylosing spondylitis. Eur J Immunol. 1995;25:3199–201.PubMedCrossRef D’Amato M, Fiorillo MT, Carcassi C, et al. Relevance of residue 116 of HLA-B27 in determining susceptibility to ankylosing spondylitis. Eur J Immunol. 1995;25:3199–201.PubMedCrossRef
68.
go back to reference Ramos M, López de Castro JA. HLA-B27 and the pathogenesis of spondyloarthritis. Tissue Antigens. 2002;60:191–205.PubMedCrossRef Ramos M, López de Castro JA. HLA-B27 and the pathogenesis of spondyloarthritis. Tissue Antigens. 2002;60:191–205.PubMedCrossRef
69.
go back to reference Cauli A, Vacca A, Mameli A, et al. A Sardinian patient with ankylosing spondylitis and HLA-B*2709 co-occurring with HLA-B*1403. Arthritis Rheum. 2007;56:2807–9.PubMedCrossRef Cauli A, Vacca A, Mameli A, et al. A Sardinian patient with ankylosing spondylitis and HLA-B*2709 co-occurring with HLA-B*1403. Arthritis Rheum. 2007;56:2807–9.PubMedCrossRef
70.
go back to reference Olivieri I, D’Angelo S, Scarano E, Santospirito V, Padula A. The HLA-B*2709 subtype in a woman with early ankylosing spondylitis. Arthritis Rheum. 2007;56:2805–7.PubMedCrossRef Olivieri I, D’Angelo S, Scarano E, Santospirito V, Padula A. The HLA-B*2709 subtype in a woman with early ankylosing spondylitis. Arthritis Rheum. 2007;56:2805–7.PubMedCrossRef
71.
go back to reference Fiorillo MT, Cauli A, Carcassi C, et al. Two distinctive HLA haplotypes harbor the B27 alleles negatively or positively associated with ankylosing spondylitis in Sardinia: implications for disease pathogenesis. Arthritis Rheum. 2003;48:1385–9.PubMedCrossRef Fiorillo MT, Cauli A, Carcassi C, et al. Two distinctive HLA haplotypes harbor the B27 alleles negatively or positively associated with ankylosing spondylitis in Sardinia: implications for disease pathogenesis. Arthritis Rheum. 2003;48:1385–9.PubMedCrossRef
72.
go back to reference Cascino I, Paladini F, Belfiore F, et al. Identification of previously unrecognized predisposing factors for ankylosing spondylitis from analysis of HLA-B27 extended haplotypes in Sardinia. Arthritis Rheum. 2007;56:2640–51.PubMedCrossRef Cascino I, Paladini F, Belfiore F, et al. Identification of previously unrecognized predisposing factors for ankylosing spondylitis from analysis of HLA-B27 extended haplotypes in Sardinia. Arthritis Rheum. 2007;56:2640–51.PubMedCrossRef
73.
go back to reference López-Larrea C, Sujirachato K, Mehra NK, et al. HLA-B27 subtypes in Asian patients with ankylosing spondylitis. Evidence for new associations. Tissue antigens. 1995;45:169–76.PubMedCrossRef López-Larrea C, Sujirachato K, Mehra NK, et al. HLA-B27 subtypes in Asian patients with ankylosing spondylitis. Evidence for new associations. Tissue antigens. 1995;45:169–76.PubMedCrossRef
74.
go back to reference Gonzalez-Roces S, Alvarez MV, Gonzalez S, et al. HLA-B27 polymorphism and worldwide susceptibility to ankylosing spondylitis. Tissue Antigens. 1997;49:116–23.PubMedCrossRef Gonzalez-Roces S, Alvarez MV, Gonzalez S, et al. HLA-B27 polymorphism and worldwide susceptibility to ankylosing spondylitis. Tissue Antigens. 1997;49:116–23.PubMedCrossRef
75.
go back to reference Varnavidou-Nicolaidou A, Karpasitou K, Georgiou D, et al. HLA-B27 in the Greek Cypriot population: distribution of subtypes in patients with ankylosing spondylitis and other HLA-B27-related diseases. The possible protective role of B*2707. Human Immunol. 2004;65:1451–4.CrossRef Varnavidou-Nicolaidou A, Karpasitou K, Georgiou D, et al. HLA-B27 in the Greek Cypriot population: distribution of subtypes in patients with ankylosing spondylitis and other HLA-B27-related diseases. The possible protective role of B*2707. Human Immunol. 2004;65:1451–4.CrossRef
76.
77.
go back to reference Taurog JD, Maika SD, Simmons WA, Breban M, Hammer RE. Susceptibility to inflammatory disease in HLA-B27 transgenic rat lines correlates with the level of B27 expression. J Immunol. 1993;150:4168–78.PubMed Taurog JD, Maika SD, Simmons WA, Breban M, Hammer RE. Susceptibility to inflammatory disease in HLA-B27 transgenic rat lines correlates with the level of B27 expression. J Immunol. 1993;150:4168–78.PubMed
78.
go back to reference Cauli A, Dessole G, Passiu G, Mathieu A. Quantification of cellular antigens by means of flow cytometry and its role in rheumatology. Reumatismo. 2001;53:14–7.PubMed Cauli A, Dessole G, Passiu G, Mathieu A. Quantification of cellular antigens by means of flow cytometry and its role in rheumatology. Reumatismo. 2001;53:14–7.PubMed
79.
go back to reference Poncelet P. Microbeads and flow cytometry: how and why put the “-metry” in immuno-cytometry? Ann Biol Clin (Paris). 2004;62(1):53–7. Poncelet P. Microbeads and flow cytometry: how and why put the “-metry” in immuno-cytometry? Ann Biol Clin (Paris). 2004;62(1):53–7.
80.
go back to reference Cauli A, Dessole G, Nurchis PP, et al. The role of HLA-B27 molecules in the pathogenesis of ankylosing spondylitis. Reumatismo. 2002;54(3):266–71.PubMed Cauli A, Dessole G, Nurchis PP, et al. The role of HLA-B27 molecules in the pathogenesis of ankylosing spondylitis. Reumatismo. 2002;54(3):266–71.PubMed
81.
go back to reference Cauli A, Dessole G, Fiorillo MT, et al. Increased level of HLA-B27 expression in ankylosing spondylitis patients compared with healthy HLA-B27 positive subjects: a possible further susceptibility factor for the development of disease. Rheumatology (Oxford). 2002;41(12):1375–9.CrossRef Cauli A, Dessole G, Fiorillo MT, et al. Increased level of HLA-B27 expression in ankylosing spondylitis patients compared with healthy HLA-B27 positive subjects: a possible further susceptibility factor for the development of disease. Rheumatology (Oxford). 2002;41(12):1375–9.CrossRef
82.
go back to reference Ebringer A, Ahmadi K, Fielder M, et al. Molecular mimicry: the geographical distribution of immune responses to Klebsiella in ankylosing spondylitis and its relevance to therapy. Clin Rheumatol. 1996;15:57–67.PubMedCrossRef Ebringer A, Ahmadi K, Fielder M, et al. Molecular mimicry: the geographical distribution of immune responses to Klebsiella in ankylosing spondylitis and its relevance to therapy. Clin Rheumatol. 1996;15:57–67.PubMedCrossRef
83.
go back to reference Tsuchiya N, Husby G, Williams RC Jr, Stieglitz H, Lipsky PE, Inman RD. Autoantibodies to HLA-B27 sequence cross-react with the hypothetical peptide from the arthritis—associated Shigella plasmid. J Clin Invest. 1990;85:1193–203.CrossRef Tsuchiya N, Husby G, Williams RC Jr, Stieglitz H, Lipsky PE, Inman RD. Autoantibodies to HLA-B27 sequence cross-react with the hypothetical peptide from the arthritis—associated Shigella plasmid. J Clin Invest. 1990;85:1193–203.CrossRef
84.
go back to reference Fiorillo MT, Maragno M, Butler R, Dupuis ML, Sorrentino R. CD8+ T cell auto-reactivity to HLA-B27-restricted self-epitope correlates with ankylosing spondylitis. J Clin Invest. 2000;106:47–53.PubMedPubMedCentralCrossRef Fiorillo MT, Maragno M, Butler R, Dupuis ML, Sorrentino R. CD8+ T cell auto-reactivity to HLA-B27-restricted self-epitope correlates with ankylosing spondylitis. J Clin Invest. 2000;106:47–53.PubMedPubMedCentralCrossRef
85.
go back to reference Mear JP, Schreiber KL, Münz C, et al. Misfolding of HLA-B27 as a result of its B pocket suggests a novel mechanism for its role in susceptibility to spondyloarthropathies. J Immunol. 1999;163:6665–70.PubMed Mear JP, Schreiber KL, Münz C, et al. Misfolding of HLA-B27 as a result of its B pocket suggests a novel mechanism for its role in susceptibility to spondyloarthropathies. J Immunol. 1999;163:6665–70.PubMed
86.
go back to reference Lipsky PE. Spondyloarthopathies. In: Klippel JH, Dieppe PA, editors. Rheumatology 2nd ed. London: Mosby, 1999: 6.12.1–12. Lipsky PE. Spondyloarthopathies. In: Klippel JH, Dieppe PA, editors. Rheumatology 2nd ed. London: Mosby, 1999: 6.12.1–12.
87.
go back to reference Khare SD, Hansen J, Luthra HS, David CS. HLA-B27 heavy chains contribute to spontaneous inflammatory disease in B27/human beta 2-microglobulin (beta2 m) double transgenic mice with disrupted mouse beta2m. J Clin Invest. 1996;98:2746–55.PubMedPubMedCentralCrossRef Khare SD, Hansen J, Luthra HS, David CS. HLA-B27 heavy chains contribute to spontaneous inflammatory disease in B27/human beta 2-microglobulin (beta2 m) double transgenic mice with disrupted mouse beta2m. J Clin Invest. 1996;98:2746–55.PubMedPubMedCentralCrossRef
88.
go back to reference Allen RL, O’Callaghan CA, McMichael AJ, Bowness P. Cutting edge: HLA-B27 can form a novel beta 2-microglobulin-free heavy chain homodimer structure. J immunol. 1999;162:5045–8.PubMed Allen RL, O’Callaghan CA, McMichael AJ, Bowness P. Cutting edge: HLA-B27 can form a novel beta 2-microglobulin-free heavy chain homodimer structure. J immunol. 1999;162:5045–8.PubMed
89.
go back to reference Kim TH, Stone MA, Rahman P, et al. Interleukin 1 and nuclear factor-kappaB polymorphism in ankylosing spondylitis in Canada and Korea. J Rheumatol. 2005;32:1907–10.PubMed Kim TH, Stone MA, Rahman P, et al. Interleukin 1 and nuclear factor-kappaB polymorphism in ankylosing spondylitis in Canada and Korea. J Rheumatol. 2005;32:1907–10.PubMed
90.
go back to reference Sims AM, Timms AE, Bruges-Armas J, et al. Prospective meta-analysis of interleukin 1 gene complex polymorphisms confirm associations with ankylosing spondylitis. Ann Rheum Dis. 2008;67:1305–9.PubMedCrossRef Sims AM, Timms AE, Bruges-Armas J, et al. Prospective meta-analysis of interleukin 1 gene complex polymorphisms confirm associations with ankylosing spondylitis. Ann Rheum Dis. 2008;67:1305–9.PubMedCrossRef
91.
go back to reference Maksymowych WP, Rahman P, Reeve JP, Gladman DD, Peddle L, Inman RD. Association of the IL1 gene cluster with susceptibility to ankylosing spondylitis: an analysis of three Canadian populations. Arthritis Rheum. 2006;54:974–85.PubMedCrossRef Maksymowych WP, Rahman P, Reeve JP, Gladman DD, Peddle L, Inman RD. Association of the IL1 gene cluster with susceptibility to ankylosing spondylitis: an analysis of three Canadian populations. Arthritis Rheum. 2006;54:974–85.PubMedCrossRef
92.
go back to reference Niki Y, Yamada H, Kikuchi T, et al. Membrane associated IL-1 contributes to chronic synovitis and cartilage destruction in human IL-1 alpha transegenic mice. J Immunol. 2004;172:577–84.PubMedCrossRef Niki Y, Yamada H, Kikuchi T, et al. Membrane associated IL-1 contributes to chronic synovitis and cartilage destruction in human IL-1 alpha transegenic mice. J Immunol. 2004;172:577–84.PubMedCrossRef
93.
go back to reference Tan AL, Marzo-Ortega H, O’Connor P, Fraser A, Emery P, McGonagle D. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis. 2004;63:1041–5.PubMedPubMedCentralCrossRef Tan AL, Marzo-Ortega H, O’Connor P, Fraser A, Emery P, McGonagle D. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis. 2004;63:1041–5.PubMedPubMedCentralCrossRef
94.
go back to reference Haibel H, Rudwaleit M, Listing J, Sieper J. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis. 2005;64:296–8.PubMedPubMedCentralCrossRef Haibel H, Rudwaleit M, Listing J, Sieper J. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis. 2005;64:296–8.PubMedPubMedCentralCrossRef
95.
go back to reference Yan J, Parekh VV, Mendez-Fernandez Y, et al. In vivo role of ER-associated peptidase activity in tailoring peptides for presentation by MHC class Ia and class Ib molecules. J Exp Med. 2006;203:647–59.PubMedPubMedCentralCrossRef Yan J, Parekh VV, Mendez-Fernandez Y, et al. In vivo role of ER-associated peptidase activity in tailoring peptides for presentation by MHC class Ia and class Ib molecules. J Exp Med. 2006;203:647–59.PubMedPubMedCentralCrossRef
96.
go back to reference Hammer ND, Schmidt JC, Chapman MR. The curli nucleator protein, CsgB, contains an amyloidogenic domain that directs CsgA polymerization. Proc Natl Acad Sci USA. 2007;104:12494–9.PubMedPubMedCentralCrossRef Hammer ND, Schmidt JC, Chapman MR. The curli nucleator protein, CsgB, contains an amyloidogenic domain that directs CsgA polymerization. Proc Natl Acad Sci USA. 2007;104:12494–9.PubMedPubMedCentralCrossRef
98.
go back to reference Wendling D. Interleukin 23: a key cytokine in chronic inflammatory disease. Joint Bone Spine. 2008;75:517–9.PubMedCrossRef Wendling D. Interleukin 23: a key cytokine in chronic inflammatory disease. Joint Bone Spine. 2008;75:517–9.PubMedCrossRef
99.
go back to reference Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukin 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol. 2007;8:942–9.PubMedCrossRef Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukin 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol. 2007;8:942–9.PubMedCrossRef
100.
go back to reference Zheng Y, Valdez PA, Danilenko DM, et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med. 2008;14:282–9.PubMedCrossRef Zheng Y, Valdez PA, Danilenko DM, et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med. 2008;14:282–9.PubMedCrossRef
101.
go back to reference Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356:580–92.PubMedCrossRef Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356:580–92.PubMedCrossRef
102.
go back to reference Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial. (PHOENIX 2). Lancet. 2008;371:1675–84.PubMedCrossRef Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial. (PHOENIX 2). Lancet. 2008;371:1675–84.PubMedCrossRef
104.
go back to reference Rudwaleit M, Siegert S, Yin Z, et al. Low T cell production of TNF alpha and INF gamma in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. Ann Rheum Dis. 2001;60:36–42.PubMedPubMedCentralCrossRef Rudwaleit M, Siegert S, Yin Z, et al. Low T cell production of TNF alpha and INF gamma in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. Ann Rheum Dis. 2001;60:36–42.PubMedPubMedCentralCrossRef
105.
go back to reference Smith JA, Barnes MD, Hong D, DeLay ML, Inman RD, Colbert RA. Gene expression analysis of macrophages derived from ankylosing spondylitis patients reveals interferon-gamma dysregulation. Arthritis Rheum. 2008;58(6):1640–9.PubMedPubMedCentralCrossRef Smith JA, Barnes MD, Hong D, DeLay ML, Inman RD, Colbert RA. Gene expression analysis of macrophages derived from ankylosing spondylitis patients reveals interferon-gamma dysregulation. Arthritis Rheum. 2008;58(6):1640–9.PubMedPubMedCentralCrossRef
107.
go back to reference van der Heijde D, Machado P, Braun J, et al. MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel analysis in patients with ankylosing spondylitis. Ann Rheum Dis. 2012;71(3):369–73.PubMedCrossRef van der Heijde D, Machado P, Braun J, et al. MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel analysis in patients with ankylosing spondylitis. Ann Rheum Dis. 2012;71(3):369–73.PubMedCrossRef
108.
go back to reference Schett G, Rudwaleit M. Can we stop progression of ankylosing spondylitis ? Best Pract Res Clin Rheumatol. 2010;24(3):363–71.PubMedCrossRef Schett G, Rudwaleit M. Can we stop progression of ankylosing spondylitis ? Best Pract Res Clin Rheumatol. 2010;24(3):363–71.PubMedCrossRef
109.
go back to reference Sieper J, Appel H, Braun J, Rudwaleit M. Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes. Arthritis Rheum. 2008;58(3):649–56.PubMedCrossRef Sieper J, Appel H, Braun J, Rudwaleit M. Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes. Arthritis Rheum. 2008;58(3):649–56.PubMedCrossRef
110.
go back to reference Hermann KG, Baraliakos X, van der Heijde DM, et al. Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI study group. Ann Rheum Dis. 2012;71(8):1278–88.PubMedCrossRef Hermann KG, Baraliakos X, van der Heijde DM, et al. Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI study group. Ann Rheum Dis. 2012;71(8):1278–88.PubMedCrossRef
111.
go back to reference Chiowchanwisawakit P, Lambert RG, Conner-Spady B, Maksymowych WP. Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis. Arthritis Rheum. 2011;63(8):2215–25.PubMedCrossRef Chiowchanwisawakit P, Lambert RG, Conner-Spady B, Maksymowych WP. Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis. Arthritis Rheum. 2011;63(8):2215–25.PubMedCrossRef
112.
go back to reference Maksymowych WP, Chiowchanwisawakit P, Clare T, Pedersen SJ, Østergaard M, Lambert RG. Inflammatory lesions of the spine on magnetic resonance predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. Arthritis Rheum. 2009;60(1):93–102.PubMedCrossRef Maksymowych WP, Chiowchanwisawakit P, Clare T, Pedersen SJ, Østergaard M, Lambert RG. Inflammatory lesions of the spine on magnetic resonance predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. Arthritis Rheum. 2009;60(1):93–102.PubMedCrossRef
Metadata
Title
The synovio-entheseal complex in enthesoarthritis
Authors
Angelo De Cata
Michele Inglese
Rosa Rubino
Francesca Molinaro
Gianluigi Mazzoccoli
Publication date
01-05-2016
Publisher
Springer International Publishing
Published in
Clinical and Experimental Medicine / Issue 2/2016
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-015-0341-x

Other articles of this Issue 2/2016

Clinical and Experimental Medicine 2/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.